查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1908129

泛基因组检测和多基因panel检测（MGPT）市场规模、份额和趋势分析报告：按检测方法、适应症、最终用途、地区和细分市场预测，2025-2033年

Pan-genomic And Multi-gene Panel Testing Market Size, Share & Trends Analysis Report By Test, By Application, By End-use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

泛基因组检测与多基因panel检测（MGPT）市场概述

2024 年全球泛基因组检测/MGPT 市场规模估计为 89.6 亿美元，预计到 2033 年将达到 231.9 亿美元。

预计2025年至2033年间，该市场将以11.37%的复合年增长率增长，主要驱动因素包括肿瘤学和精准医学领域临床应用的不断扩大、对全面基因资讯的需求日益增长、分子谱分析在治疗方案製定中的应用日益广泛，以及高通量定序技术的进步。与传统的单基因检测相比，针对数十至数百个癌症相关基因的多基因检测能够提供更深入、更全面的分子资讯。

临床检验的检测方法，例如 FoundationOne CDx（约 324 个基因）和 MSK-IMPACT（468 个基因），目前已在 CLIA 认证的检查室中常规用于识别具有治疗意义的基因组改变。这有助于提高治疗方法方案的个人化程度，使临床医生能够透过一次全面的分析来识别罕见但可靶向的突变，而无需耗费大量时间进行一系列单独的检测。因此，领先的癌症中心正在将 MGPT/泛基因组检测纳入其肿瘤诊疗流程。真实世界的结果证实了这种做法的显着影响。根据美国临床肿瘤学会 (ASCO) 2024 年 11 月的一项研究，在接受病理学家主导的全面基因组分析 (CGP) 的患者中，有 36% 的患者仅根据其基因组谱中的生物标记观察就接受了标靶治疗(TT) 或免疫肿瘤治疗 (IO)。

此外，推动泛基因组检测/多基因检测（MGPT）市场成长的关键因素之一是定序成本的快速持续下降。根据美国国家人类基因组研究所（NHGRI）的报告，次世代定序（NGS）技术的显着进步已将单一人类基因定序成本从2001年的约1亿美元降至2024年的约6亿美元。虽然全面的多基因检测曾经是一项专业且昂贵的流程，但成本的大幅降低使其成为患者和诊断检查室都能轻鬆获得且负担得起的工具。因此，遗传性癌症检测正从主要在专业遗传中心使用转变为预防医学和肿瘤学工作流程中的标准组成部分。

全球遗传性疾病和新兴遗传性疾病盛行率的不断上升是泛基因组学和多基因全基因组检测（MGPT）市场最强劲的驱动力之一。据估计，全球约有4亿人患有罕见遗传性疾病，3-5%的新生儿受到先天性或遗传性疾病的影响。随着越来越多的疾病的遗传基础逐渐明晰，医疗保健系统正迅速将广泛的多基因和全基因组检测纳入早期诊断、携带者筛检、治疗决策和长期疾病管理的标准通讯协定。人们对林奇症候群、李-弗劳梅尼症候群以及BRCA相关乳癌和卵巢癌等遗传性癌症症候群的认识不断提高，显着促进了这些检测方法在肿瘤学领域的应用。由于5-10%的癌症被归类为遗传性癌症，而BRCA1/2基因突变可使乳癌风险增加高达70%，卵巢癌风险增加高达40%，因此，积极全面的基因组筛检的需求从未如此迫切。

此外，基因组数据的日益复杂化，特别是来自泛基因组检测和多基因检测（MGPT）的数据，带来了巨大的挑战，因为解读数百万个突变需要临床基因组学和生物资讯学的高级专业知识。许多实验室难以留住足够的分子遗传学家、临床遗传学家和生物资讯学家来应对如此繁重的工作量。根据发表在PMC上的《肿瘤学次世代定序（NGS）全球应用框架》，训练有素的临床分子遗传学家和基因组分析师的短缺阻碍了NGS的广泛应用。此外，定序和生物资讯学流程的基础设施差异加剧了这个问题，使得各实验室难以维持一致的品质。

目录

第一章 泛基因组检测与MGPT市场：调查方法与范围

2.泛基因组检测与MGPT市场：执行摘要

  • 市场概览
  • 检查
  • 适应症概述
  • 最终用途概述
  • 竞争格局概述

3.泛基因组检测/多基因检测市场变数、趋势与范围

  • 市场区隔和范围
  • 市场体系展望
    • 母市场展望
    • 相关/辅助市场展望
  • 市场动态
  • 市场驱动因素分析
    • 肿瘤学和精准医学的临床应用
    • 定序成本下降和技术进步
    • 遗传性疾病的发生率正在上升。
  • 市场限制因素分析
    • 数据解读的复杂性和基因组学专家的短缺
    • 监管挑战、合规负担和缺乏标准化
  • 波特五力分析
  • PESTLE分析
  • 管道分析

第四章 泛基因组检测与MGPT市场：依检测方式分類的估算与趋势分析

  • 泛基因组检测与MGPT市场：依检测方法进行的变异分析
  • 泛基因组/全EXOME组检测板
  • 综合遗传疾病检测
  • 肿瘤多基因检测
  • 药物基因体学（PGx）检测组

第五章 泛基因组检测与MGPT市场：依适应症分類的估算与趋势分析

  • 泛基因组检测与MGPT市场：依适应症分類的变异分析
  • 肿瘤学
  • 心臟病学/心肌病
  • 神经病学和神经遗传学
  • 罕见且未确诊的遗传疾病
  • 生殖携带者筛检
  • 新生儿和儿童基因组学

6. 泛基因组检测和MGPT市场：按最终用途分類的估算和趋势分析

  • 泛基因组检测与MGPT市场：依最终用途分類的差异分析
  • 医院的基因检查室
  • 独立诊断检查室
  • 专业基因组学中心
  • 其他的

7. 泛基因组检测与MGPT市场：按地区分類的业务分析

  • 区域市场概览
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东和非洲

第八章 竞争情势

  • 公司分类
  • 策略规划
    • 新产品发布
    • 合伙
    • 获得
    • 合资
    • 资金筹措
  • 主要企业市占率分析（2024 年）
  • 公司热力图分析
  • 公司简介
    • Illumina, Inc.
    • Thermo Fisher Scientific, Inc.
    • Fulgent Genetics
    • Ambry Genetics（Tempus）
    • GeneDx
    • Baylor Genetics
    • Natera
    • Caris Life Sciences
    • Foundation Medicine, Inc.（Roche）
    • Guardant Health
Product Code: GVR-4-68040-830-3

Pan-genomic And Multi-gene Panel Testing Market Summary

The global pan-genomic & multi-gene panel testing market size was estimated at USD 8.96 billion in 2024 and is projected to reach USD 23.19 billion by 2033, growing at a CAGR of 11.37% from 2025 to 2033, driven by driven by clinical adoption in oncology and precision medicine and increasing demand for comprehensive genetic insights, rising use of molecular profiling in treatment planning, and advancements in high-throughput sequencing technologies. Compared to traditional single-gene assays, multi-gene panels that often span dozens to hundreds of cancer-related genes provide deeper and more comprehensive molecular insights.

Clinically validated assays, such as FoundationOne CDx (approximately 324 genes) and MSK-IMPACT (468 genes), are now routinely used in CLIA-certified laboratories to identify actionable genomic alterations. This has improved therapeutic matching, enabling clinicians to identify rare but targetable variants through a single, comprehensive analysis, rather than relying on sequential, time-consuming individual tests. As a result, major cancer centers are incorporating multi-gene and pan-genomic testing into their oncology workflows. Real-world results demonstrate the quantifiable impact of this adoption. A November 2024 study from the American Society of Clinical Oncology (ASCO) found that 36% of patients who underwent pathologist-directed comprehensive genomic profiling (CGP) received a targeted therapy (TT) or immuno-oncology (IO) agent simply because of biomarker findings in their genomic profile.

Moreover, the one of the key factors propelling the growth of the pan-genomic and multi-gene panel testing market is the swift and ongoing decrease in sequencing costs. The National Human Genome Research Institute (NHGRI) reports that significant advancements in next-generation sequencing (NGS) technologies have enabled the cost of sequencing a human genome to decrease from nearly USD 100 million in 2001 to approximately USD 600 in 2024. Comprehensive multi-gene testing was once a specialized and expensive process, but thanks to this significant decrease, it is now a readily available and reasonably priced tool for both patients and diagnostic laboratories. As a result, hereditary cancer testing has shifted from being used primarily in specialized genetics centers to becoming a standard component of preventive care and oncology workflows.

The rising global prevalence of genetic disorders, both inherited and newly occurring, has become one of the strongest drivers of the pan-genomic and multi-gene panel testing market. An estimated 400 million people worldwide suffer from rare genetic disorders, and 3-5% of all newborns are impacted by congenital or inherited genetic conditions. Healthcare systems are quickly incorporating extensive multi-gene and pan-genomic testing into standard protocols for early diagnosis, carrier screening, therapeutic decision-making, and long-term disease management as the genetic basis of more diseases becomes more apparent. Adoption in oncology is being greatly increased by the growing recognition of hereditary cancer syndromes, such as Lynch syndrome, Li-Fraumeni syndrome, and BRCA-associated breast/ovarian cancer. With 5-10% of all cancers classified as hereditary, and BRCA1/2 mutations increasing breast cancer risk by up to 70% and ovarian cancer risk by up to 40%, the need for proactive and comprehensive genomic screening has never been more compelling.

In addition, the increasing complexity of genomic data, particularly from whole-genome and large multi-gene panel tests, poses a significant challenge because interpreting millions of variants necessitates extensive clinical genomics and bioinformatics expertise. Many laboratories struggle to find enough molecular geneticists, clinical geneticists, and bioinformaticians to handle the workload. According to a global adoption framework for NGS in oncology published in PMC, a shortage of well-trained personnel, such as clinical molecular geneticists and genomic analysts, impedes widespread implementation. Moreover, infrastructural gaps in sequencing and bioinformatics pipelines exacerbate the issue, making it difficult to maintain consistent quality across laboratories.

Global Pan-genomic And Multi-gene Panel Testing Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global pan-genomic & multi-gene panel testing market report based on test, application, end-use, and region:

  • Test Outlook (Revenue, USD Million, 2021 - 2033)
  • Pan-Genomic / Whole Exome Based Panels
  • Comprehensive Hereditary Disease Panels
  • Oncology Multi-Gene Panels
  • Pharmacogenomics (PGx) Panels
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Oncology
  • Cardiology & Cardiomyopathy
  • Neurology and Neurogenetics
  • Rare & Undiagnosed Genetic Diseases
  • Reproductive Carrier Screening
  • Newborn & Pediatric Genomics
  • End-use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital-based Genetic Labs
  • Independent Diagnostic Labs
  • Specialty Genomic Centers
  • Others
  • Regional Outlook (USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • Thailand
    • South Korea
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Pan-Genomic & Multi-Gene Panel Testing Market: Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Test
      • 1.1.1.2. Application Segment
      • 1.1.1.3. End Use Segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Pan-Genomic & Multi-Gene Panel Testing Market: Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Test
  • 2.3. Application Snapshot
  • 2.4. End Use Snapshot
  • 2.5. Competitive Landscape Snapshot

Chapter 3. Pan-Genomic & Multi-Gene Panel Testing Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers Analysis
    • 3.4.1. Clinical adoption in oncology and precision medicine
    • 3.4.2. Falling sequencing costs & tech advances
    • 3.4.3. Increasing burden of genetic disorders & rising
  • 3.5. Market Restraint Analysis
    • 3.5.1. Complexity of data interpretation & shortage of skilled genomic specialists
    • 3.5.2. Regulatory challenges, compliance Burdens & lack of standardization
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis
  • 3.8. Pipeline Analysis

Chapter 4. Pan-Genomic & Multi-Gene Panel Testing Market: Test Estimates & Trend Analysis

  • 4.1. Pan-Genomic & Multi-Gene Panel Testing Market: Test Movement Analysis
  • 4.2. Pan-Genomic / Whole Exome Based Panels
    • 4.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3. Comprehensive Hereditary Disease Panels
    • 4.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4. Oncology Multi-Gene Panels
    • 4.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Pharmacogenomics (PGx) Panels
    • 4.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Pan-Genomic & Multi-Gene Panel Testing Market: Application Estimates & Trend Analysis

  • 5.1. Pan-Genomic & Multi-Gene Panel Testing Market: Application Movement Analysis
  • 5.2. Oncology
    • 5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.3. Cardiology & Cardiomyopathy
    • 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4. Neurology and Neurogenetics
    • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Rare & Undiagnosed Genetic Diseases
    • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Reproductive Carrier Screening
    • 5.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7. Newborn & Pediatric Genomics
    • 5.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Pan-Genomic & Multi-Gene Panel Testing Market: End Use Estimates & Trend Analysis

  • 6.1. Pan-Genomic & Multi-Gene Panel Testing Market: End Use Movement Analysis
  • 6.2. Hospital-based Genetic Labs
    • 6.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3. Independent Diagnostic Labs
    • 6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4. Specialty Genomic Centers
    • 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Others
    • 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Pan-Genomic & Multi-Gene Panel Testing Market: Regional Business Analysis

  • 7.1. Regional Market Snapshot
  • 7.2. North America
    • 7.2.1. North America Pan-Genomic & Multi-Gene Panel Testing Market Estimates and Forecast, 2021 - 2033 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
      • 7.2.2.2. Key Country Dynamics
      • 7.2.2.3. Regulatory Framework
      • 7.2.2.4. Reimbursement Scenario
      • 7.2.2.5. Competitive Scenario
    • 7.2.3. Canada
      • 7.2.3.1. Canada Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
      • 7.2.3.2. Key Country Dynamics
      • 7.2.3.3. Regulatory Framework
      • 7.2.3.4. Reimbursement Scenario
      • 7.2.3.5. Competitive Scenario
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
      • 7.2.4.2. Key Country Dynamics
      • 7.2.4.3. Regulatory Framework
      • 7.2.4.4. Reimbursement Scenario
      • 7.2.4.5. Competitive Scenario
  • 7.3. Europe
    • 7.3.1. Europe Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
      • 7.3.2.2. Key Country Dynamics
      • 7.3.2.3. Regulatory Framework
      • 7.3.2.4. Reimbursement Scenario
      • 7.3.2.5. Competitive Scenario
    • 7.3.3. Germany
      • 7.3.3.1. Germany Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
      • 7.3.3.2. Key Country Dynamics
      • 7.3.3.3. Regulatory Framework
      • 7.3.3.4. Reimbursement Scenario
      • 7.3.3.5. Competitive Scenario
    • 7.3.4. Spain
      • 7.3.4.1. Spain Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
      • 7.3.4.2. Key Country Dynamics
      • 7.3.4.3. Regulatory Framework
      • 7.3.4.4. Reimbursement Scenario
      • 7.3.4.5. Competitive Scenario
    • 7.3.5. France
      • 7.3.5.1. France Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
      • 7.3.5.2. Key Country Dynamics
      • 7.3.5.3. Regulatory Framework
      • 7.3.5.4. Reimbursement Scenario
      • 7.3.5.5. Competitive Scenario
    • 7.3.6. Italy
      • 7.3.6.1. Italy Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
      • 7.3.6.2. Key Country Dynamics
      • 7.3.6.3. Regulatory Framework
      • 7.3.6.4. Reimbursement Scenario
      • 7.3.6.5. Competitive Scenario
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
      • 7.3.7.2. Key Country Dynamics
      • 7.3.7.3. Regulatory Framework
      • 7.3.7.4. Reimbursement Scenario
      • 7.3.7.5. Competitive Scenario
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
      • 7.3.8.2. Key Country Dynamics
      • 7.3.8.3. Regulatory Framework
      • 7.3.8.4. Reimbursement Scenario
      • 7.3.8.5. Competitive Scenario
    • 7.3.9. Norway
      • 7.3.9.1. Norway Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
      • 7.3.9.2. Key Country Dynamics
      • 7.3.9.3. Regulatory Framework
      • 7.3.9.4. Reimbursement Scenario
      • 7.3.9.5. Competitive Scenario
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
      • 7.4.2.2. Key Country Dynamics
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Scenario
      • 7.4.2.5. Competitive Scenario
    • 7.4.3. China
      • 7.4.3.1. China Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
      • 7.4.3.2. Key Country Dynamics
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Scenario
      • 7.4.3.5. Competitive Scenario
    • 7.4.4. India
      • 7.4.4.1. India Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
      • 7.4.4.2. Key Country Dynamics
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Scenario
      • 7.4.4.5. Competitive Scenario
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
      • 7.4.5.2. Key Country Dynamics
      • 7.4.5.3. Regulatory Framework
      • 7.4.5.4. Reimbursement Scenario
      • 7.4.5.5. Competitive Scenario
    • 7.4.6. Thailand
      • 7.4.6.1. Thailand Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
      • 7.4.6.2. Key Country Dynamics
      • 7.4.6.3. Regulatory Framework
      • 7.4.6.4. Reimbursement Scenario
      • 7.4.6.5. Competitive Scenario
    • 7.4.7. Australia
      • 7.4.7.1. Australia Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
      • 7.4.7.2. Key Country Dynamics
      • 7.4.7.3. Regulatory Framework
      • 7.4.7.4. Reimbursement Scenario
      • 7.4.7.5. Competitive Scenario
  • 7.5. Latin America
    • 7.5.1. Latin America Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
      • 7.5.2.2. Key Country Dynamics
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Scenario
      • 7.5.2.5. Competitive Scenario
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
      • 7.5.3.2. Key Country Dynamics
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Scenario
      • 7.5.3.5. Competitive Scenario
  • 7.6. MEA
    • 7.6.1. MEA Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
      • 7.6.2.2. Key Country Dynamics
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Scenario
      • 7.6.2.5. Competitive Scenario
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
      • 7.6.3.2. Key Country Dynamics
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Scenario
      • 7.6.3.5. Competitive Scenario
    • 7.6.4. UAE
      • 7.6.4.1. UAE Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
      • 7.6.4.2. Key Country Dynamics
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Scenario
      • 7.6.4.5. Competitive Scenario
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
      • 7.6.5.2. Key Country Dynamics
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Scenario
      • 7.6.5.5. Competitive Scenario

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
    • 8.2.1. New Product Launch
    • 8.2.2. Partnerships
    • 8.2.3. Acquisition
    • 8.2.4. Collaboration
    • 8.2.5. Funding
  • 8.3. Key Company Market Share Analysis, 2024
  • 8.4. Company Heat Map Analysis
  • 8.5. Company Profiles
    • 8.5.1. Illumina, Inc.
      • 8.5.1.1. Company Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Thermo Fisher Scientific, Inc.
      • 8.5.2.1. Company Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Fulgent Genetics
      • 8.5.3.1. Company Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Ambry Genetics (Tempus)
      • 8.5.4.1. Company Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. GeneDx
      • 8.5.5.1. Company Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Baylor Genetics
      • 8.5.6.1. Company Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Natera
      • 8.5.7.1. Company Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Caris Life Sciences
      • 8.5.8.1. Company Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Foundation Medicine, Inc. (Roche)
      • 8.5.9.1. Company Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Guardant Health
      • 8.5.10.1. Company Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List Of Secondary Sources
  • Table 2 List Of Abbreviation
  • Table 3 Global Pan-Genomic & Multi-Gene Panel Testing Market, By Region, 2021 - 2033 (USD Million)
  • Table 4 Global Pan-Genomic & Multi-Gene Panel Testing Market, By Test, 2021 - 2033 (USD Million)
  • Table 5 Global Pan-Genomic & Multi-Gene Panel Testing Market, By Application, 2021 - 2033 (USD Million)
  • Table 6 Global Pan-Genomic & Multi-Gene Panel Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 7 North America Pan-Genomic & Multi-Gene Panel Testing Market, By Country, 2021 - 2033 (USD Million)
  • Table 8 North America Pan-Genomic & Multi-Gene Panel Testing Market, By Test, 2021 - 2033 (USD Million)
  • Table 9 North America Pan-Genomic & Multi-Gene Panel Testing Market, By Application, 2021 - 2033 (USD Million)
  • Table 10 North America Pan-Genomic & Multi-Gene Panel Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 11 U.S. Pan-Genomic & Multi-Gene Panel Testing Market, By Test, 2021 - 2033 (USD Million)
  • Table 12 U.S. Pan-Genomic & Multi-Gene Panel Testing Market, By Application, 2021 - 2033 (USD Million)
  • Table 13 U.S. Pan-Genomic & Multi-Gene Panel Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 14 Canada Pan-Genomic & Multi-Gene Panel Testing Market, By Test, 2021 - 2033 (USD Million)
  • Table 15 Canada Pan-Genomic & Multi-Gene Panel Testing Market, By Application, 2021 - 2033 (USD Million)
  • Table 16 Canada Pan-Genomic & Multi-Gene Panel Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 17 Mexico Pan-Genomic & Multi-Gene Panel Testing Market, By Test, 2021 - 2033 (USD Million)
  • Table 18 Mexico Pan-Genomic & Multi-Gene Panel Testing Market, By Application, 2021 - 2033 (USD Million)
  • Table 19 Mexico Pan-Genomic & Multi-Gene Panel Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 20 Europe Pan-Genomic & Multi-Gene Panel Testing Market, By Country, 2021 - 2033 (USD Million)
  • Table 21 Europe Pan-Genomic & Multi-Gene Panel Testing Market, By Test, 2021 - 2033 (USD Million)
  • Table 22 Europe Pan-Genomic & Multi-Gene Panel Testing Market, By Application, 2021 - 2033 (USD Million)
  • Table 23 Europe Pan-Genomic & Multi-Gene Panel Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 24 UK Pan-Genomic & Multi-Gene Panel Testing Market, By Test, 2021 - 2033 (USD Million)
  • Table 25 UK Pan-Genomic & Multi-Gene Panel Testing Market, By Application, 2021 - 2033 (USD Million)
  • Table 26 UK Pan-Genomic & Multi-Gene Panel Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 27 Germany Pan-Genomic & Multi-Gene Panel Testing Market, By Test, 2021 - 2033 (USD Million)
  • Table 28 Germany Pan-Genomic & Multi-Gene Panel Testing Market, By Application, 2021 - 2033 (USD Million)
  • Table 29 Germany Pan-Genomic & Multi-Gene Panel Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 30 France Pan-Genomic & Multi-Gene Panel Testing Market, By Test, 2021 - 2033 (USD Million)
  • Table 31 France Pan-Genomic & Multi-Gene Panel Testing Market, By Application, 2021 - 2033 (USD Million)
  • Table 32 France Pan-Genomic & Multi-Gene Panel Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 33 Italy Pan-Genomic & Multi-Gene Panel Testing Market, By Test, 2021 - 2033 (USD Million)
  • Table 34 Italy Pan-Genomic & Multi-Gene Panel Testing Market, By Application, 2021 - 2033 (USD Million)
  • Table 35 Italy Pan-Genomic & Multi-Gene Panel Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 36 Spain Pan-Genomic & Multi-Gene Panel Testing Market, By Test, 2021 - 2033 (USD Million)
  • Table 37 Spain Pan-Genomic & Multi-Gene Panel Testing Market, By Application, 2021 - 2033 (USD Million)
  • Table 38 Spain Pan-Genomic & Multi-Gene Panel Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 39 Sweden Pan-Genomic & Multi-Gene Panel Testing Market, By Test, 2021 - 2033 (USD Million)
  • Table 40 Sweden Pan-Genomic & Multi-Gene Panel Testing Market, By Application, 2021 - 2033 (USD Million)
  • Table 41 Sweden Pan-Genomic & Multi-Gene Panel Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 42 Norway Pan-Genomic & Multi-Gene Panel Testing Market, By Test, 2021 - 2033 (USD Million)
  • Table 43 Norway Pan-Genomic & Multi-Gene Panel Testing Market, By Application, 2021 - 2033 (USD Million)
  • Table 44 Norway Pan-Genomic & Multi-Gene Panel Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 45 Denmark Pan-Genomic & Multi-Gene Panel Testing Market, By Test, 2021 - 2033 (USD Million)
  • Table 46 Denmark Pan-Genomic & Multi-Gene Panel Testing Market, By Application, 2021 - 2033 (USD Million)
  • Table 47 Denmark Pan-Genomic & Multi-Gene Panel Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 48 Asia Pacific Pan-Genomic & Multi-Gene Panel Testing Market, By Country, 2021 - 2033 (USD Million)
  • Table 49 Asia Pacific Pan-Genomic & Multi-Gene Panel Testing Market, By Test, 2021 - 2033 (USD Million)
  • Table 50 Asia-Pacific Pan-Genomic & Multi-Gene Panel Testing Market, By Application, 2021 - 2033 (USD Million)
  • Table 51 Asia Pacific Pan-Genomic & Multi-Gene Panel Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 52 Japan Pan-Genomic & Multi-Gene Panel Testing Market, By Test, 2021 - 2033 (USD Million)
  • Table 53 Japan Pan-Genomic & Multi-Gene Panel Testing Market, By Application, 2021 - 2033 (USD Million)
  • Table 54 Japan Pan-Genomic & Multi-Gene Panel Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 55 China Pan-Genomic & Multi-Gene Panel Testing Market, By Test, 2021 - 2033 (USD Million)
  • Table 56 China Pan-Genomic & Multi-Gene Panel Testing Market, By Application, 2021 - 2033 (USD Million)
  • Table 57 China Pan-Genomic & Multi-Gene Panel Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 58 India Pan-Genomic & Multi-Gene Panel Testing Market, By Test, 2021 - 2033 (USD Million)
  • Table 59 India Pan-Genomic & Multi-Gene Panel Testing Market, By Application, 2021 - 2033 (USD Million)
  • Table 60 India Pan-Genomic & Multi-Gene Panel Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 61 Australia Pan-Genomic & Multi-Gene Panel Testing Market, By Test, 2021 - 2033 (USD Million)
  • Table 62 Australia Pan-Genomic & Multi-Gene Panel Testing Market, By Application, 2021 - 2033 (USD Million)
  • Table 63 Australia Pan-Genomic & Multi-Gene Panel Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 64 Thailand Pan-Genomic & Multi-Gene Panel Testing Market, By Test, 2021 - 2033 (USD Million)
  • Table 65 Thailand Pan-Genomic & Multi-Gene Panel Testing Market, By Application, 2021 - 2033 (USD Million)
  • Table 66 Thailand Pan-Genomic & Multi-Gene Panel Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 67 South Korea Pan-Genomic & Multi-Gene Panel Testing Market, By Test, 2021 - 2033 (USD Million)
  • Table 68 South Korea Pan-Genomic & Multi-Gene Panel Testing Market, By Application, 2021 - 2033 (USD Million)
  • Table 69 South Korea Pan-Genomic & Multi-Gene Panel Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 70 Latin America Pan-Genomic & Multi-Gene Panel Testing Market, By Country, 2021 - 2033 (USD Million)
  • Table 71 Latin America Pan-Genomic & Multi-Gene Panel Testing Market, By Test, 2021 - 2033 (USD Million)
  • Table 72 Latin America Pan-Genomic & Multi-Gene Panel Testing Market, By Application, 2021 - 2033 (USD Million)
  • Table 73 Latin America Pan-Genomic & Multi-Gene Panel Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 74 Brazil Pan-Genomic & Multi-Gene Panel Testing Market, By Test, 2021 - 2033 (USD Million)
  • Table 75 Brazil Pan-Genomic & Multi-Gene Panel Testing Market, By Application, 2021 - 2033 (USD Million)
  • Table 76 Brazil Pan-Genomic & Multi-Gene Panel Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 77 Argentina Pan-Genomic & Multi-Gene Panel Testing Market, By Test, 2021 - 2033 (USD Million)
  • Table 78 Argentina Pan-Genomic & Multi-Gene Panel Testing Market, By Application, 2021 - 2033 (USD Million)
  • Table 79 Argentina Pan-Genomic & Multi-Gene Panel Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 80 MEA Pan-Genomic & Multi-Gene Panel Testing Market, By Country, 2021 - 2033 (USD Million)
  • Table 81 MEA Pan-Genomic & Multi-Gene Panel Testing Market, By Test, 2021 - 2033 (USD Million)
  • Table 82 MEA Pan-Genomic & Multi-Gene Panel Testing Market, By Application, 2021 - 2033 (USD Million)
  • Table 83 MEA Pan-Genomic & Multi-Gene Panel Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 84 South Africa Pan-Genomic & Multi-Gene Panel Testing Market, By Test, 2021 - 2033 (USD Million)
  • Table 85 South Africa Pan-Genomic & Multi-Gene Panel Testing Market, By Application, 2021 - 2033 (USD Million)
  • Table 86 South Africa Pan-Genomic & Multi-Gene Panel Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 87 Saudi Arabia Pan-Genomic & Multi-Gene Panel Testing Market, By Test, 2021 - 2033 (USD Million)
  • Table 88 Saudi Arabia Pan-Genomic & Multi-Gene Panel Testing Market, By Application, 2021 - 2033 (USD Million)
  • Table 89 Saudi Arabia Pan-Genomic & Multi-Gene Panel Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 90 UAE Pan-Genomic & Multi-Gene Panel Testing Market, By Test, 2021 - 2033 (USD Million)
  • Table 91 UAE Pan-Genomic & Multi-Gene Panel Testing Market, By Application, 2021 - 2033 (USD Million)
  • Table 92 UAE Pan-Genomic & Multi-Gene Panel Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 93 Kuwait Pan-Genomic & Multi-Gene Panel Testing Market, By Test, 2021 - 2033 (USD Million)
  • Table 94 Kuwait Pan-Genomic & Multi-Gene Panel Testing Market, By Application, 2021 - 2033 (USD Million)
  • Table 95 Kuwait Pan-Genomic & Multi-Gene Panel Testing Market, By End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Pan-genomic & multi-gene panel testing market segmentation
  • Fig. 2 Data analysis test technique
  • Fig. 3 Market formulation and validation
  • Fig. 4 Data validating & publishing
  • Fig. 5 Market research process
  • Fig. 6 Information procurement
  • Fig. 7 Primary research
  • Fig. 8 Value-chain-based sizing & forecasting
  • Fig. 9 QFD biomarker modelling for market share assessment
  • Fig. 10 Market formulation & validation
  • Fig. 11 Commodity flow analysis
  • Fig. 12 Market outlook
  • Fig. 13 Segment snapshot-1
  • Fig. 14 Segment snapshot-2
  • Fig. 15 Competitive landscape snapshot
  • Fig. 16 Market trends & outlook
  • Fig. 17 Porter's five force analysis
  • Fig. 18 PESTEL analysis
  • Fig. 19 Pan-genomic & multi-gene panel testing market Test outlook key takeaways
  • Fig. 20 Pan-genomic & multi-gene panel testing market: Test movement analysis
  • Fig. 21 Pan-genomic / whole exome based panels market estimates, 2021 - 2033 (USD Million)
  • Fig. 22 Comprehensive hereditary disease panels market estimates, 2021 - 2033 (USD Million)
  • Fig. 23 Oncology multi-gene panels market estimates, 2021 - 2033 (USD Million)
  • Fig. 24 Pharmacogenomics (PGx) panels market estimates, 2021 - 2033 (USD Million)
  • Fig. 25 Pan-genomic & multi-gene panel testing market: Application outlook key takeaways
  • Fig. 26 Pan-genomic & multi-gene panel testing market: Application movement analysis
  • Fig. 27 Oncology market estimates, 2021 - 2033 (USD Million)
  • Fig. 28 Cardiology & cardiomyopathy market estimates, 2021 - 2033 (USD Million)
  • Fig. 29 Neurology and neurogenetics market estimates, 2021 - 2033 (USD Million)
  • Fig. 30 Rare & undiagnosed genetic diseases market estimates, 2021 - 2033 (USD Million)
  • Fig. 31 Reproductive carrier screening market estimates, 2021 - 2033 (USD Million)
  • Fig. 32 Newborn & pediatric genomics market estimates, 2021 - 2033 (USD Million)
  • Fig. 33 Pan-genomic & multi-gene panel testing market: End Use outlook key takeaways
  • Fig. 34 Pan-genomic & multi-gene panel testing market: End Use movement analysis
  • Fig. 35 Hospital-based genetic labs market estimates, 2021 - 2033 (USD Million)
  • Fig. 36 Independent diagnostic labs market estimates, 2021 - 2033 (USD Million)
  • Fig. 37 Specialty genomic centers market estimates, 2021 - 2033 (USD Million)
  • Fig. 38 Others market estimates, 2021 - 2033 (USD Million)
  • Fig. 39 Regional marketplace: Key takeaways
  • Fig. 40 Middle East
  • Fig. 41 Middle East market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 42 Saudi Arabia key country dynamics
  • Fig. 43 Saudi Arabia market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 44 UAE key country dynamics
  • Fig. 45 UAE market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 46 Kuwait key country dynamics
  • Fig. 47 Kuwait market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 48 Oman key country dynamics
  • Fig. 49 Oman market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 50 Qatar key country dynamics
  • Fig. 51 Qatar market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 52 Rest of Middle East key country dynamics
  • Fig. 53 Rest of Middle East market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 54 Market differentiators
  • Fig. 55 Key company market share analysis